John D. Ratliff is CEO & Covance Drug Development at LABORATORY CORP OF AMERICA HOLDINGS (LH). They have made 1 open-market trade across 1 company since 2013, most recently 2019-04-03.
CIK 0001575951
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| Q | SELL | 2013-11-18 | 2013-11-19 | $42.55 | $9.0M | -6.2% | -1.0% | -1.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.